Vaxcyte, Inc. (PCVX)

Over the past six months, Vaxcyte, Inc. (PCVX) stock has seen a positive performance, with gains ranging from 26.50% to 28.30%. Key events impacting the stock price include the Q3 2025 financial results, where Vaxcyte reported an EPS of -$1.56, missing analysts' expectations, but provided a business update including positive final data from the VAX-24 infant Phase 2 dose-finding study and an expected cash runway into mid-2028. Vaxcyte announced plans to establish fill-finish manufacturing in North Carolina through an agreement with Thermo Fisher Scientific. Vaxcyte dosed the first participants in the OPUS Phase 3 trial evaluating VAX-31. Fintel reported a 19.72% increase in Vaxcyte's (PCVX) price target to $99.96. The Motley Fool reported that Vaxcyte's Chief Technical Operations Officer sold shares.

As a clinical-stage biotechnology company, Vaxcyte, Inc.'s primary focus is on the research, development, and clinical trials of vaccine candidates rather than commercial sales of approved products. Therefore, there is no explicit information available regarding demand seasonality for Vaxcyte's products and services. The company's customer base is expected to include pharmaceutical companies and government agencies involved in vaccine development and distribution, with plans for partnerships for commercialization.

Vaxcyte, Inc. is a clinical-stage biotechnology company focused on vaccine innovation, dedicated to developing novel protein vaccines to prevent or treat bacterial infectious diseases. The company operates within the Healthcare sector and the Biotechnology industry, leveraging its proprietary XpressCF cell-free protein synthesis platform to engineer broad-spectrum conjugate and novel protein vaccines. Its major product candidates include VAX-24, a 24-valent pneumococcal conjugate vaccine (PCV) candidate; VAX-31, a 31-valent PCV candidate; VAX-A1, a novel conjugate vaccine candidate; VAX-PG, a therapeutic vaccine candidate; and VAX-GI, a preclinical vaccine candidate.

Vaxcyte, Inc. is headquartered in San Carlos, California, United States, with operations spanning various countries. Vaxcyte's stock is listed on NASDAQ and also trades on several European exchanges, including Munich, Frankfurt, Stuttgart, Dusseldorf, Hamburg, Berne, and Milan Stock Exchanges. The company is also establishing fill-finish manufacturing in North Carolina as part of its long-term U.S. commercial supply strategy.

Vaxcyte's brand reputation in the past year has been shaped by positive clinical developments and analyst confidence, alongside some market skepticism. Positive events include positive clinical trial results, Breakthrough Therapy Designation for VAX-31, analyst confidence with a "Strong Buy" consensus, and strategic manufacturing investment. Challenges include underwhelming VAX-24 infant trial expectations, a tougher regulatory stance on vaccines, and a Q3 2025 earnings miss.

Vaxcyte, Inc. (PCVX) has significant institutional ownership, with institutional shareholders holding approximately 107.91% to 108.96% of the company's stock, and insiders holding about 15.26%. Major institutional owners include Janus Henderson Group Plc, Fmr Llc, Vanguard Group Inc, Ra Capital Management, L.p., BlackRock, Inc., T. Rowe Price Investment Management, Inc., Wellington Management Group Llp, State Street Corp, D. E. Shaw & Co., Inc., and VTSMX - Vanguard Total Stock Market Index Fund Investor Shares. Tpg Group Holdings Sbs Advisors Inc is identified as the largest individual Vaxcyte shareholder, owning 3.88% of the company's shares.